Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis

Autoimmunity Reviews

Volumn 15, Issue 3, 2016, Pages 203-209

  Moulis, Guillaume ^a   Audemard Verger, Alexandra ^b   Arnaud, Laurent ^c   Luxembourger, Cécile ^a   Montastruc, François ^a   Gaman, Amelia Maria ^d,e   Svenungsson, Elisabet ^f   Ruggeri, Marco ^g   Mahévas, Matthieu ^h   Gerfaud Valentin, Mathieu ⁱ   Brainsky, Andres ^j   Michel, Marc ^h   Godeau, Bertrand ^h   Lapeyre Mestre, Maryse ^a   Sailler, Laurent ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^d UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^e Pediatric Clinic   (Romania)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g SAN BORTOLO HOSPITAL   (Italy)

^h French National Center for Autoimmune Cytopenias   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

^j GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

HUMAN; MEDLINE; META ANALYSIS; PRIMARY IMMUNE RESPONSE; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS; WEB OF SCIENCE; ANIMAL; ANTIPHOSPHOLIPID SYNDROME; COMPLICATION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY; RISK;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RISK; THROMBOSIS;

EID: 84958836609     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.11.001     Document Type: Review

References (38)

1. Lo E., Deane S. Diagnosis and classification of immune-mediated thrombocytopenia. Autoimmun Rev 2014, 13:577-583.
2. Sarpatwari A., Bennett D., Logie J.W., Shukla A., Beach K.J., Newland A.C., et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010, 95:1167-1175.
3. Severinsen M.T., Engebjerg M.C., Farkas D.K., Jensen A.Ø., Nørgaard M., Zhao S., et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2011, 152:360-362.
4. Nørgaard M., Severinsen M.T., Lund Maegbaek M., Jensen A.Ø., Cha S., Sørensen H.T. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2012, 159:109-111.
5. Zöller B., Li X., Sundquist J., Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012, 379:244-249.
6. Yusuf H.R., Hooper W.C., Beckman M.G., Zhang Q.C., Tsai J., Ortel T.L. Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases. J Thromb Thrombolysis 2014, 38:306-313.
7. Yusuf H.R., Hooper W.C., Grosse S.D., Parker C.S., Boulet S.L., Ortel T.L. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res 2015, 135:50-57.
8. Uthman I., Godeau B., Taher A., Khamashta M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev 2008, 22:187-194.
9. Bidot C.J., Jy W., Horstman L.L., Ahn E.R., Yaniz M., Ahn Y.S. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol 2006, 81:391-396.
10. Stasi R., Stipa E., Masi M., Oliva F., Sciarra A., Perrotti A., et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994, 84:4203-4208.
11. Pierrot-Deseilligny Despujol C., Michel M., Khellaf M., Gouault M., Intrator L., Bierling P., et al. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol 2008, 142:638-643.
12. Yang Y.-J., Yun G.-W., Song I.-C., Baek S.-W., Lee K.-S., Ryu H.W., et al. Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia. Korean J Intern Med 2011, 26:449-454.
13. Kim K.-J., Baek I.-W., Yoon C.-H., Kim W.-U., Cho C.-S. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol 2013, 161:706-714.
14. George J.N., Woolf S.H., Raskob G.E., Wasser J.S., Aledort L.M., Ballem P.J., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996, 88:3-40.
15. Neunert C., Lim W., Crowther M., Cohen A., Solberg L., Crowther M.A. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117:4190-4207.
16. Diz-Küçükkaya R., Hacihanefioğlu A., Yenerel M., Turgut M., Keskin H., Nalçaci M., et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001, 98:1760-1764.
17. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P.A., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009, 62:e1-34.
18. Wells G., Shea B., O'Connell D., Peterson J., Welch V., Losos M., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Available at:, Accessed October 1st, 2015. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
19. Sweeting M.J., Sutton A.J., Lambert P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004, 23:1351-1375.
20. Higgins J.P.T., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in Meta-analyses. BMJ 2003, 327:557-560.
21. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
22. Dash S., Marwaha R.K. Mohanty S. Lupus anticoagulant in immune thrombocytopenic purpura. Indian J Pediatr 2004, 71:505-507.
23. Moulis G., Delavigne K., Huguet F., Fortenfant F., Beyne-Rauzy O., Adoue D. Antiphospholipid antibodies and the risk of thrombosis: a comparative survey between chronic immune thrombocytopenia and primary antiphospholipid syndrome. Rev Med Interne 2011, 32:724-729.
24. Gaman A.M., Gaman G.D., Rotaru I. The antiphospholipid antibodies, a risk factor to develop antiphospholipid syndrome or systemic lupus erythematosus in patients with immune thrombocytopenic purpura (ITP). Haematologica 2013, 98:742.
25. Wong R.S.M., Bakshi K., Brainsky A. Thrombophilia in patients with chronic immune thrombocytopenia. Scand J Clin Lab Invest 2015, 75:13-17.
26. Ruggeri M., Tosetto A., Palandri F., Polverelli N., Mazzucconi M.G., Santoro C., et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost 2014, 12:1266-1273.
27. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
28. Wisløff F., Jacobsen E.M., Liestøl S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2002, 108:263-271.
29. Brandt J.T., Triplett D.A., Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. on behalf of the subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the ISTH. Thromb Haemost 1995, 74:1185-1190.
30. Pengo V., Biasiolo A., Pegoraro C., Cucchini U., Noventa F., Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005, 93:1147-1152.
31. Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003, 101:1827-1832.
32. Vikerfors A., Johansson A.-B., Gustafsson J.T., Jönsen A., Leonard D., Zickert A., et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford) 2013, 52:501-509.
33. Bertolaccini M.L., Amengual O., Andreoli L., Atsumi T., Chighizola C.B., Forastiero R., et al. 14th International Congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014, 13:917-930.
34. Lipp E., von Felten A., Sax H., Müller D., Berchtold P. Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia. Eur J Haematol 1998, 60:283-288.
35. Reynaud Q., Lega J.-C., Mismetti P., Chapelle C., Wahl D., Cathébras P., et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2014, 13:595-608.
36. Moulis G., Lapeyre-Mestre M., Montastruc J.-L., Sailler L. Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. Autoimmun Rev 2015, 14:168-173.
37. Erkan D., Aguiar C.L., Andrade D., Cohen H., Cuadrado M.J., Danowski A., et al. 14th International Congress on antiphospholipid antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014, 13:685-696.
38. Noel N., Dutasta F., Costedoat-Chalumeau N., Bienvenu B., Mariette X., Geffray L., et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev 2015, 14:680-685.